<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906087</url>
  </required_header>
  <id_info>
    <org_study_id>Merck IISP#31911</org_study_id>
    <secondary_id>Merck IISP#31911</secondary_id>
    <nct_id>NCT00906087</nct_id>
  </id_info>
  <brief_title>Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions</brief_title>
  <acronym>Myoc Gene</acronym>
  <official_title>The Effect of Myocilin Genetic Variants on Intraocular Pressure and Blood Pressure Variation in Sitting and Supine Positions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if one of the genes that can cause glaucoma, called
      myocilin, are associated with larger eye pressure and blood pressure changes in sitting and
      lying down positions without glaucoma drug treatment and with glaucoma drug treatment with a
      combination medication called CosoptÂ® (Merck &amp; Co., Inc.).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is an important public health issue, and identifying new markers to improve
      treatment outcomes is a high priority. Progress in Mendelian genetic approaches has led to
      identifying 15 genes and 31 loci (http://www.ncbi.nlm.nih.gov/); however, since these
      monogenic forms of glaucoma are uncommon, other approaches are needed to identify genetic
      markers that contribute to common risk factors, such as elevated eye pressure, eye pressure
      fluctuation, and drug response variation.

      It is well known that eye pressure varies over a 24-hour period,1-6 but the mechanisms that
      regulate this eye pressure rhythm are not yet fully known. Drance reported that 84% of normal
      eyes (N=320 eyes) had eye pressure fluctuations of less than 5 mmHg in contrast to only 6% of
      untreated glaucomatous eyes (N=138).7 Drance clearly recognized that eye pressure factors
      were more variable in eyes with glaucoma. Attention to this eye pressure fluctuation during
      glaucoma treatment is important because fluctuation leads to progression. The variation in
      eye pressure drug response profiles measured at selected times over a 24-hour period is
      related to the mechanism of action of these drugs, endogenous circadian rhythms, and
      glaucoma. The molecular and genetic tools are now available to identify potential genetic
      markers for these variable traits.

      Advancing clinical research to the &quot;translational&quot; level is an important step to integrate
      our ever increasing knowledge base in genomics and proteinomics with clinical trials and
      clinical studies. Given the infrastructure at the University of Michigan with the strength in
      both glaucoma genetics and our resources in the clinic, it is possible to test for
      relationships between glaucoma genes and eye pressure. Although it is known that myocilin
      (MYOC) mutations cause the phenotype of high pressure open-angle glaucoma, the effect of
      these MYOC mutations in &quot;pre-symptomatic&quot; subjects and patients with early open-angle
      glaucoma on eye pressure variation is not known.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 4, 2009</start_date>
  <completion_date type="Actual">July 18, 2012</completion_date>
  <primary_completion_date type="Actual">July 18, 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure in Sitting and Supine Positions.</measure>
    <time_frame>10 weeks</time_frame>
    <description>Effect of Cosopt treatment on intraocular pressure changes in sitting to supine positions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure in Sitting to Supine Positions</measure>
    <time_frame>10 weeks</time_frame>
    <description>Effect of Cosopt treatment on blood pressure changes in sitting to supine positions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocilin Mutation Arg272Gly in Subjects</measure>
    <time_frame>10 week study</time_frame>
    <description>Number of subjects with Myocilin Arg272Gly</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Cosopt</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosopt (combination eyedrop of dorzolamide and timolol)</intervention_name>
    <description>One drop in each eye every twelve hours for six weeks</description>
    <arm_group_label>Cosopt</arm_group_label>
    <other_name>Cosopt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early OAG, as determined by a comprehensive ophthalmic examination

          -  Greater than or equal to 18 years of age

          -  Either gender

          -  Any race

          -  Both eyes meet eligibility criteria

          -  Cup to disc ratio less than 0.8 determined by fundoscopy and confirmed by disc photos

          -  Visual field parameters in the study eye: Pattern Standard Deviation (PSD) greater
             than 1.0 dB but less than 6.0 dB

          -  Ability to cooperate for an outpatient study involving at least five visits over a
             four month study period

          -  Ability to comply with Cosopt treatment regimen

        Exclusion Criteria:

          -  Less than or equal to 18 years old

          -  Refusal to be genotyped or sign Informed Consent for Protocol 1991-144

          -  Pregnant or lactating women

          -  Medical conditions of severe pulmonary compromise with asthma or emphysema or cardiac
             contraindications to beta-blockers

          -  Ocular disease of chronic angle-closure glaucoma, iridocorneal endothelial disease,
             posterior polymorphous corneal dystrophy, epithelial downgrowth, uveitic glaucoma, or
             neovascular glaucoma

          -  Ocular surgery for glaucoma, including trabeculectomy, other glaucoma filtration
             surgery, glaucoma drainage implant, or laser cyclophotocoagulation

          -  Current use of systemic steroids or chemotherapeutic agents that non-selectively
             inhibit dividing cells

          -  Proliferative diabetic retinopathy, history of panretinal photocoagulation treatment,
             diabetic macular edema, or history of macular grid laser treatment

          -  History of changing treatment involving the use oral beta-blockers, angiotensin
             converting enzyme inhibitors, calcium channel blockers, or oral alpha 2-agonists in
             the prior two months or in the next month (i.e., must be on stable treatment with any
             of these drugs for at least two months)

          -  Patients taking erectile dysfunction drugs (i.e., Viagra, Cialis, Levitra)

          -  Contradictions:

               -  bronchial asthma or a history of bronchial asthma

               -  severe chronic obstructive pulmonary disease

               -  sinus bradycardia

               -  second or third degree atrioventricular block

               -  overt cardiac failure

               -  cardiogenic shock

               -  hypersensitivity to any component of Cosopt
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sayoko E Moroi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Department of Ophthalmology and Visual Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>W.K. Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <results_first_submitted>March 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Sayoko E. Moroi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Myocilin gene</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>dorzolamide and timolol combination eyedrop</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cosopt</title>
          <description>Cosopt 1 drop two times daily was administered for 6 weeks.
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Screening</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Begin Washout</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Washout and Continue Protocol</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Cosopt Treatment 6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Final Washout Period 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cosopt</title>
          <description>Cosopt 1 drop two times daily was administered for 6 weeks.
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Number of males and females</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure right eye</title>
          <description>Baseline intraocular pressure = on current treatment</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Baseline at initial visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.6" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 4 week washout</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intraocular pressure left eye</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Baseline at initial visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 4 week washout</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.4" spread="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure in Sitting and Supine Positions.</title>
        <description>Effect of Cosopt treatment on intraocular pressure changes in sitting to supine positions.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cosopt</title>
            <description>Intraocular pressure comparison after washout of Cosopt and while on treatment with Cosopt
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure in Sitting and Supine Positions.</title>
          <description>Effect of Cosopt treatment on intraocular pressure changes in sitting to supine positions.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting right eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting left eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine right eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine left eye</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure in Sitting to Supine Positions</title>
        <description>Effect of Cosopt treatment on blood pressure changes in sitting to supine positions.</description>
        <time_frame>10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cosopt</title>
            <description>Cosopt 1 drop two times daily was administered for 6 weeks.
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure in Sitting to Supine Positions</title>
          <description>Effect of Cosopt treatment on blood pressure changes in sitting to supine positions.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.6" spread="20.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.8" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" spread="12.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="16.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocilin Mutation Arg272Gly in Subjects</title>
        <description>Number of subjects with Myocilin Arg272Gly</description>
        <time_frame>10 week study</time_frame>
        <population>Only 1 participant had a MYOC mutation in the 3 exons</population>
        <group_list>
          <group group_id="O1">
            <title>Cosopt</title>
            <description>Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Myocilin Mutation Arg272Gly in Subjects</title>
          <description>Number of subjects with Myocilin Arg272Gly</description>
          <population>Only 1 participant had a MYOC mutation in the 3 exons</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of study participation (2 week washout; 6 weeks on Cosopt; 4 weeks washout)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cosopt</title>
          <description>Cosopt 1 drop two times daily was administered for 6 weeks.
Cosopt (combination eyedrop of dorzolamide and timolol): One drop in each eye every twelve hours for six weeks</description>
        </group>
        <group group_id="E2">
          <title>Washout (no Glaucoma Medication)</title>
          <description>After appropriate washout, no glaucoma medication was administered for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pressure greater than 30 mmHg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor wants an opportunity to review the data. I will send a PDF of this record on 3/17/2017.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sayoko E. Moroi</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-763-3732</phone>
      <email>smoroi@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

